Gut taste receptor type 1 member 3 is an intrinsic regulator of Western diet-induced intestinal inflammation.
Butyrate-producing microbes
Clostridia
Gut-taste receptor
Inflammatory bowel disease
Intestinal PPAR-γ
Taste receptor type 1 member 3
Western diet
mTOR signaling
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
28 04 2023
28 04 2023
Historique:
received:
25
08
2022
accepted:
24
03
2023
medline:
1
5
2023
pubmed:
29
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Long-term intake of a Western diet (WD), characterized by a high-fat content and sugary drinks, is hypothesized to contribute to the development of inflammatory bowel disease (IBD). Despite the identified clinical association, the molecular mechanisms by which dietary changes contribute to IBD development remain unknown. Therefore, we examined the influence of long-term intake of a WD on intestinal inflammation and the mechanisms by which WD intake affects IBD development. Mice fed normal diet or WD for 10 weeks, and bowel inflammation was evaluated through pathohistological and infiltrated inflammatory cell assessments. To understand the role of intestinal taste receptor type 1 member 3 (TAS1R3) in WD-induced intestinal inflammation, cultured enteroendocrine cells harboring TAS1R3, subjected to RNA interference or antagonist treatment, and Tas1r3-deficient mice were used. RNA-sequencing, flow cytometry, 16S metagenomic sequencing, and bioinformatics analyses were performed to examine the involved mechanisms. To demonstrate their clinical relevance, intestinal biopsies from patients with IBD and mice with dextran sulfate sodium-induced colitis were analyzed. Our study revealed for the first time that intestinal TAS1R3 is a critical mediator of WD-induced intestinal inflammation. WD-fed mice showed marked TAS1R3 overexpression with hallmarks of serious bowel inflammation. Conversely, mice lacking TAS1R3 failed to exhibit inflammatory responses to WD. Mechanistically, intestinal transcriptome analysis revealed that Tas1r3 deficiency suppressed mTOR signaling, significantly increasing the expression of PPARγ (a major mucosal defense enhancer) and upregulating the expression of PPARγ target-gene (tight junction protein and antimicrobial peptide). The gut microbiota of Tas1r3-deficient mice showed expansion of butyrate-producing Clostridia. Moreover, an increased expression of host PPARγ-signaling pathway proteins was positively correlated with butyrate-producing microbes, suggesting that intestinal TAS1R3 regulates the relationship between host metabolism and gut microflora in response to dietary factors. In cultured intestinal cells, regulation of the TAS1R3-mTOR-PPARγ axis was critical for triggering an inflammatory response via proinflammatory cytokine production and secretion. Abnormal regulation of the axis was observed in patients with IBD. Our findings suggest that the TAS1R3-mTOR-PPARγ axis in the gut links Western diet consumption with intestinal inflammation and is a potential therapeutic target for IBD.
Sections du résumé
BACKGROUND
Long-term intake of a Western diet (WD), characterized by a high-fat content and sugary drinks, is hypothesized to contribute to the development of inflammatory bowel disease (IBD). Despite the identified clinical association, the molecular mechanisms by which dietary changes contribute to IBD development remain unknown. Therefore, we examined the influence of long-term intake of a WD on intestinal inflammation and the mechanisms by which WD intake affects IBD development.
METHODS
Mice fed normal diet or WD for 10 weeks, and bowel inflammation was evaluated through pathohistological and infiltrated inflammatory cell assessments. To understand the role of intestinal taste receptor type 1 member 3 (TAS1R3) in WD-induced intestinal inflammation, cultured enteroendocrine cells harboring TAS1R3, subjected to RNA interference or antagonist treatment, and Tas1r3-deficient mice were used. RNA-sequencing, flow cytometry, 16S metagenomic sequencing, and bioinformatics analyses were performed to examine the involved mechanisms. To demonstrate their clinical relevance, intestinal biopsies from patients with IBD and mice with dextran sulfate sodium-induced colitis were analyzed.
RESULTS
Our study revealed for the first time that intestinal TAS1R3 is a critical mediator of WD-induced intestinal inflammation. WD-fed mice showed marked TAS1R3 overexpression with hallmarks of serious bowel inflammation. Conversely, mice lacking TAS1R3 failed to exhibit inflammatory responses to WD. Mechanistically, intestinal transcriptome analysis revealed that Tas1r3 deficiency suppressed mTOR signaling, significantly increasing the expression of PPARγ (a major mucosal defense enhancer) and upregulating the expression of PPARγ target-gene (tight junction protein and antimicrobial peptide). The gut microbiota of Tas1r3-deficient mice showed expansion of butyrate-producing Clostridia. Moreover, an increased expression of host PPARγ-signaling pathway proteins was positively correlated with butyrate-producing microbes, suggesting that intestinal TAS1R3 regulates the relationship between host metabolism and gut microflora in response to dietary factors. In cultured intestinal cells, regulation of the TAS1R3-mTOR-PPARγ axis was critical for triggering an inflammatory response via proinflammatory cytokine production and secretion. Abnormal regulation of the axis was observed in patients with IBD.
CONCLUSIONS
Our findings suggest that the TAS1R3-mTOR-PPARγ axis in the gut links Western diet consumption with intestinal inflammation and is a potential therapeutic target for IBD.
Identifiants
pubmed: 37118698
doi: 10.1186/s12916-023-02848-0
pii: 10.1186/s12916-023-02848-0
pmc: PMC10148556
doi:
Substances chimiques
PPAR gamma
0
TOR Serine-Threonine Kinases
EC 2.7.11.1
Butyrates
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Informations de copyright
© 2023. The Author(s).
Références
Nature. 2016 Jan 14;529(7585):226-30
pubmed: 26762460
Gastroenterology. 2002 Jul;123(1):86-91
pubmed: 12105836
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2392-7
pubmed: 11854532
Gastroenterology. 2011 Jul;141(1):227-36
pubmed: 21621540
Gastroenterology. 2003 May;124(5):1265-76
pubmed: 12730867
Front Microbiol. 2018 Sep 25;9:2247
pubmed: 30319571
Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):243-55
pubmed: 24393836
Int J Mol Sci. 2019 Jan 17;20(2):
pubmed: 30658440
Nat Genet. 2001 May;28(1):58-63
pubmed: 11326277
J Clin Invest. 1999 Aug;104(4):383-9
pubmed: 10449430
Trends Endocrinol Metab. 2013 Feb;24(2):92-100
pubmed: 23266105
Sci Rep. 2015 Nov 27;5:17305
pubmed: 26610689
Sci Rep. 2017 Mar 07;7:43199
pubmed: 28266623
World J Clin Pediatr. 2021 Sep 9;10(5):84-92
pubmed: 34616650
Nat Rev Gastroenterol Hepatol. 2012 Feb 21;9(4):219-30
pubmed: 22349170
Regul Pept. 2008 Oct 9;150(1-3):26-32
pubmed: 18627777
Nutrients. 2019 May 08;11(5):
pubmed: 31072001
J Nutr. 2009 Sep;139(9):1619-25
pubmed: 19625695
Eur J Nutr. 2021 Feb;60(1):345-356
pubmed: 32333097
Mol Cell. 2012 Sep 28;47(6):851-62
pubmed: 22959271
J Biol Chem. 2005 Apr 15;280(15):15238-46
pubmed: 15668251
J Clin Immunol. 2007 May;27(3):275-83
pubmed: 17510806
Proc Natl Acad Sci U S A. 2010 May 11;107(19):8772-7
pubmed: 20421464
Gastroenterology. 2003 May;124(5):1315-24
pubmed: 12730872
Nat Immunol. 2004 Jan;5(1):104-12
pubmed: 14691478
Endocrinology. 2001 Oct;142(10):4522-8
pubmed: 11564718
Pharmacol Res. 2010 Jun;61(6):489-98
pubmed: 20227502
Immunity. 2018 Jul 17;49(1):33-41.e7
pubmed: 30021144
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Science. 2016 Mar 18;351(6279):1329-33
pubmed: 26847546
Immune Netw. 2020 Feb 04;20(2):e15
pubmed: 32395367
Inflamm Bowel Dis. 2012 Jun;18(6):1164-76
pubmed: 21887729
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
Inflamm Bowel Dis. 2016 Mar;22(3):E11
pubmed: 26841225
J Exp Med. 2005 Apr 18;201(8):1205-15
pubmed: 15824083
Nat Rev Gastroenterol Hepatol. 2014 Jun;11(6):372-85
pubmed: 24614343
Genome Biol. 2004;5(10):R80
pubmed: 15461798
Curr Opin Cell Biol. 2011 Dec;23(6):744-55
pubmed: 21963299
Cell Metab. 2008 Dec;8(6):532-9
pubmed: 19041768
Cell Rep. 2020 Jun 30;31(13):107833
pubmed: 32610134
Biochem J. 2013 Jul 1;453(1):49-60
pubmed: 23627357
Gastroenterology. 2005 Feb;128(2):351-60
pubmed: 15685547
Lancet. 1997 Feb 15;349(9050):490-5
pubmed: 9040590
Cell. 2011 Aug 5;146(3):408-20
pubmed: 21816276
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584
pubmed: 28743984
J Crohns Colitis. 2011 Dec;5(6):566-9
pubmed: 22115376
Front Immunol. 2016 Apr 22;7:154
pubmed: 27148273
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):9-20
pubmed: 31767987
Gastroenterol Hepatol (N Y). 2015 Aug;11(8):511-20
pubmed: 27118948
Sci Rep. 2016 Jan 08;6:19032
pubmed: 26742586
Nat Genet. 2017 Feb;49(2):256-261
pubmed: 28067908
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Exp Med. 2001 Apr 2;193(7):827-38
pubmed: 11283155
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5564-5569
pubmed: 30819885
Inflamm Bowel Dis. 2016 Feb;22(2):E6-7
pubmed: 26752475
Gut. 1992 May;33(5):687-93
pubmed: 1307684
Gastroenterology. 2007 May;132(5):1791-803
pubmed: 17484875
Gut. 2006 Sep;55(9):1341-9
pubmed: 16905700
Science. 2017 Aug 11;357(6351):570-575
pubmed: 28798125
Science. 2018 Nov 30;362(6418):
pubmed: 30498100